HALO News and Press, Halozyme Therapeutics Inc. From 11/13/20

Halozyme Announces CHMP Recommends EU Approval Of Roche's Phesgo® (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For HER2-Positive Breast Cancer - Phesgo® Can be Administered in 5 t...

Halozyme Announces Janssen Submission Of Applications In US And EU Seeking Approval Of DARZALEX FASPRO™/ DARZALEX® Subcutaneous (SC) Formulation Utilizing ENHANZE® Technology, Combination With Pomalidomide And Dexamethasone For Patients With Relapsed Or Refractory Multipl...

Palm Beach, FL –November 9, 2020 – Much time and money has been allocated in the global breast cancer drug market, and multiple reports project continued growth in the sector. Early detection, increase in awareness, and incidence of breast cancer are some of the key trends sto...

MGIC Investment & Halozyme Therapeutics Set to Join S&P MidCap 400; First Bancorp, The Geo Group & Mednax to Join S&P SmallCap 600 MGIC Investment & Halozyme Therapeutics Set to Join S&P MidCap 400; First Bancorp, The Geo Group & Mednax to Join S&...

Halozyme Announces Upcoming Data Presentations at American Society of Hematology Annual Meeting For APOLLO and ANDROMEDA Phase 3 Studies By Janssen Evaluating Subcutaneous Daratumumab Utilizing ENHANZE® PR Newswire SAN DIEGO, Nov. 5, 2020 SAN DIEGO , Nov. ...

Image source: The Motley Fool. Halozyme Therapeutics Inc (NASDAQ: HALO) Q3 2020 Earnings Call Nov 2, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Halozyme Therapeutics Inc (HALO) Q3 2020 Earnings Call Transcript ...

Halozyme Therapeutics, Inc. (HALO) Q3 2020 Results Earnings Conference Call November 02, 2020, 04:30 PM ET Company Participants Al Kildani - Vice President-Investor Relations and Corporate Communications Helen Torley - President and Chief Executive Officer Elaine Sun - Chief Financial Officer...

Halozyme Therapeutics, Inc. (HALO) Q3 2020 Earnings Conference Call October 02, 2020 4:20 PM ET Company Participants Al Kildani – Vice President-Investor Relations and Corporate Communications Helen Torley – President and Chief Executive Officer Elaine Sun – Chief Financi...

The following slide deck was published by Halozyme Therapeutics, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Halozyme Therapeutics, Inc. 2020 Q3 - Results - Earnings Call Presentation

Halozyme Therapeutics (HALO): Q3 GAAP EPS of $0.25 beats by $0.05.Revenue of $65.32M (+41.3% Y/Y) beats by $5.97M.Raises 2020 Guidance: Revenues: $250-260M up from $230-245M and EPS of $0.80-0.85, up from $0.60-$0.75.Press Release For further details see: Halozyme Therapeutics EPS ...